ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Merus NV

Merus NV (2GH)

44.00
0.00
(0.00%)
Closed December 04 3:00PM
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
44.00
Bid
42.80
Ask
43.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
44.00
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
114
Financial Volume
-
VWAP
-

2GH Latest News

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit Petosemtamab bekannt

Merus gibt am ESMO-Kongress 2024 in Asien die Veröffentlichung eines Abstracts zur Behandlung von rezidivierenden/metastasierten Kopf- und Halstumoren ab der zweiten Behandlungslinie mit...

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia

Merus annonce la publication d’un résumé sur le pétosemtamab en tant que traitement de 2e ligne et au-delà pour le CETC r/m lors de l’édition 2024 du Congrès de l’ESMO Asia – Les données...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

Merus annonce sa participation aux prochaines journées Investisseurs

Merus annonce sa participation aux prochaines journées Investisseurs UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 07 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une...

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen

Merus hält Vorträge auf bevorstehenden Investorenkonferenzen UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein Unternehmen aus...

La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab

La FDA octroie à Merus un report de la date PDUFA pour le zénocutuzumab UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 nov. 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), ci-après...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.81.8518518518543.247436846.00073529DE
4-6-125051.540.49946.46118598DE
12-1.4-3.0837004405345.451.540.411447.6509915DE
26-3-6.38297872344757.540.415148.80167589DE
5220.889.655172413823.258.521.39999917044.24400398DE
15620.284.873949579823.858.51916541.98058262DE
26020.284.873949579823.858.51916541.98058262DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
P1MOrdinary Shares
0.771 €
(2,012.33%)
11.77k
BLEBluebird bio Inc
0.6568 €
(92.33%)
191.66k
PA8Paion AG
0.0184 €
(58.62%)
27.5k
9SCManganese X Energy Corp
0.0374 €
(50.81%)
54k
SQHSpearmint Resources Inc
0.017 €
(41.67%)
581.39k
4E2Relmada Therapeutics Inc
0.605 €
(-77.08%)
51.57k
L7C2Windfall Geotek Inc
0.0035 €
(-58.82%)
150.12k
R1EAEV Resources Ltd
0.0014 €
(-46.15%)
38k
BVU3St James Gold Corp
0.065 €
(-39.25%)
10k
UH7ATennant Minerals NL
0.007 €
(-39.13%)
20k
PF8European Lithium Limited
0.0318 €
(-21.67%)
24.15M
D7GNel ASA
0.2699 €
(8.92%)
7.96M
AXIAtos SE
0.3199 €
(-25.78%)
4.47M
BT81PowerHouse Energy Group Plc
0.0124 €
(0.00%)
1.85M
I5RImage Resources NL
0.059 €
(7.27%)
1.78M

Discussion

View Full Feed
ConstellationJoe ConstellationJoe 4 minutes ago
Even if this only bumps up to .0003 I'll be happy.
JAMN
TheRealMrPirate TheRealMrPirate 4 minutes ago
Okay__ 🤷
rosemountbomber rosemountbomber 4 minutes ago
Yeah this is crazy.  Between the scripts being denied and Ernie reminding me of the gooberment, I lightened up the other day. 43 sponsors.  Heck my SS Fairness Act has 330 sponsors and still waiting for the Senate to act.  SMH. 
ARDX
Schrodingers Cat Schrodingers Cat 4 minutes ago
Dec 4 short volumes: CODX 15%, FLGT 43%, QDEL 45%, VERU 42%.
CODX VERU
Real McCoy Real McCoy 4 minutes ago
And hey if it doesn’t happen you can just have your “hope” in total error.
uber darthium uber darthium 5 minutes ago
Feel like you been SPLOODGEZ ???
SPZI
Zardiw Zardiw 5 minutes ago
$TORVF - Pure Graphite Vein:

https://ddamanda.com/Charts/TORVFGraphitePicSM.jpg

Z
TORVF
manibiotech manibiotech 5 minutes ago
Usual few will not - for sure 
NWBO
forza1 forza1 5 minutes ago
Mindset shift to success 
I've been a king for 15 years now, honestly speaking - the video is nothing short of amazing and caught me by surprise.
We are so used to disappoints along the way, that sometimes it's difficult to recognize success.
A year ago all this would be daydrea
KBLB
chestypuller chestypuller 5 minutes ago
In my case, I sold 20k shares today to cover my capital gains on my sale of QQQ. Losing faith in this crew
QQQ
ITradeHbu ITradeHbu 6 minutes ago
8k out -


 
GTCH
Whalatane Whalatane 6 minutes ago
Chromo. Please tell me that those purchases are just a small part of your well diversified portfolio . Since you're in the Sth Bay I'm sure you're aware there are lots of tech Co's around you ......that are very profitable growing like crazy .
Good luck
Kiwi
AMRN
nyt nyt 7 minutes ago
Rut roh.... looks like we "touched" the fives today. Pps went to .006. There is no number lower than that, which is not into the 5's, thus no space in between, therefore 5's were touched. Anyhoo, not to worry, it's all part and parcel of the "BEST POSITION EVER", pkg.

Hey, where's tha
VPLM
CommodityCoverage CommodityCoverage 7 minutes ago
Targeting an impressive annual production of 200,000 ounces of gold, NexGold Mining (NEXG.v NXGCF) is the next mid-tier gold producer in the making, strategically capitalizing on the rising gold market, with projections that both its projects could reach $1 billion NPV at $2,500/oz gold: https://x.c
NXGCF
Zardiw Zardiw 7 minutes ago
$TORVF - CEO is a Mini Elon Musk:

https://ddamanda.com/Charts/TORVFVBond.jpg

Z
TORVF
Zardiw Zardiw 8 minutes ago
$TORVF - CEO is a Mini Elon Musk:

https://ddamanda.com/Charts/TORVFVBond.jpg

Z
TORVF
mrfence mrfence 8 minutes ago
All he needs to do is admit his mistake, that the capital rule decimal point was keyed in off to the right one digit, and explain how the GSE'S are actually over capitalized to the detriment of housing starts and by extension, the US economy.
FNMA
Hoskuld Hoskuld 8 minutes ago
Change in guidance should make that a thing of the past as of a year ago. Anavex has seemed to finish its trials adhering to its final dates pretty religiously.
AVXL
Zardiw Zardiw 9 minutes ago
$TORVF - Pure Graphite Vein:

https://ddamanda.com/Charts/TORVFGraphitePicSM.jpg

Z
TORVF
I-Glow I-Glow 9 minutes ago
You need to verify the information before you start beating your chest and shouting from the mountain top that - The Shell Risk Has Been Removed!

The sad thing is that it hasn't been removed.

"jdcpa1
Re: I-Glow post# 94068
Monday, 11/25/2024 3:28:58 PM
SPZI
Zardiw Zardiw 9 minutes ago
$TORVF - Pure Graphite Vein:

https://ddamanda.com/Charts/TORVFGraphitePicSM.jpg

Z
TORVF
iamthe walrus iamthe walrus 10 minutes ago
The shareholders call transcript and presentation slides where they listed all those partners explains a lot about the company. At that time we didn't know where these guys came from but now we know. At xtomorrow and xtequity several guys , about 6 or 7 people aren't posted as working with them as o
CRTG
Zardiw Zardiw 11 minutes ago
$TORVF - Pure Graphite Vein:

https://ddamanda.com/Charts/TORVFGraphitePicSM.jpg

Z
TORVF
nunya54 nunya54 11 minutes ago
Well, I guess you can't trust AI to tell the truth all the time. I hope everyone is buying and HOLDING, as many shares as you can get their hands on. There are only 8,807,944 shares out that the insiders do not hold. I have a chunk of that. The less stock available the higher the price when they do
ATAO

Your Recent History

Delayed Upgrade Clock